These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 36638038)

  • 1. Collaborative Therapist-Patient Decision Making: A Power-Based Exercise Program for an Adolescent With CMT1A.
    Hedgecock JB; Kelley C; Jensen A; Rapport MJ
    Pediatr Phys Ther; 2023 Jan; 35(1):101-107. PubMed ID: 36638038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive strength and balance training with the Kinect console (Xbox 360) in a patient with CMT1A.
    Pagliano E; Foscan M; Marchi A; Corlatti A; Aprile G; Riva D
    Dev Neurorehabil; 2018 Nov; 21(8):542-545. PubMed ID: 28762860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Home-based multi-sensory and proximal strengthening program to improve balance in Charcot-Marie-Tooth disease Type 1A: A proof of concept study.
    Dudziec MM; Lee LE; Massey C; Tropman D; Skorupinska M; Laurá M; Reilly MM; Ramdharry GM
    Muscle Nerve; 2024 Mar; 69(3):354-361. PubMed ID: 38156498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ascorbic acid for the treatment of Charcot-Marie-Tooth disease.
    Gess B; Baets J; De Jonghe P; Reilly MM; Pareyson D; Young P
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011952. PubMed ID: 26662471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of functional surgery associated with early intensive rehabilitation therapy in Charcot-Marie-Tooth Type 1A disease.
    Ferraro F; Dusina B; Carantini I; Strambi R; Galante E; Gaiani L
    Eur J Phys Rehabil Med; 2017 Oct; 53(5):788-793. PubMed ID: 28264542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients.
    Mannil M; Solari A; Leha A; Pelayo-Negro AL; Berciano J; Schlotter-Weigel B; Walter MC; Rautenstrauss B; Schnizer TJ; Schenone A; Seeman P; Kadian C; Schreiber O; Angarita NG; Fabrizi GM; Gemignani F; Padua L; Santoro L; Quattrone A; Vita G; Calabrese D; ; Young P; Laurà M; Haberlová J; Mazanec R; Paulus W; Beissbarth T; Shy ME; Reilly MM; Pareyson D; Sereda MW
    Neuromuscul Disord; 2014 Nov; 24(11):1003-17. PubMed ID: 25085517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome measures in the clinical evaluation of ambulatory Charcot-Marie-Tooth 1A subjects.
    Mori L; Prada V; Signori A; Pareyson D; Piscosquito G; Padua L; Pazzaglia C; Fabrizi GM; Smania N; Picelli A; Schenone A;
    Eur J Phys Rehabil Med; 2019 Feb; 55(1):47-55. PubMed ID: 29898585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats.
    Prukop T; Wernick S; Boussicault L; Ewers D; Jäger K; Adam J; Winter L; Quintes S; Linhoff L; Barrantes-Freer A; Bartl M; Czesnik D; Zschüntzsch J; Schmidt J; Primas G; Laffaire J; Rinaudo P; Brureau A; Nabirotchkin S; Schwab MH; Nave KA; Hajj R; Cohen D; Sereda MW
    J Neurosci Res; 2020 Oct; 98(10):1933-1952. PubMed ID: 32588471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance training exercise and creatine in patients with Charcot-Marie-Tooth disease.
    Chetlin RD; Gutmann L; Tarnopolsky MA; Ullrich IH; Yeater RA
    Muscle Nerve; 2004 Jul; 30(1):69-76. PubMed ID: 15221881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of foot and ankle strength training in childhood Charcot-Marie-Tooth disease.
    Burns J; Raymond J; Ouvrier R
    Neuromuscul Disord; 2009 Dec; 19(12):818-21. PubMed ID: 19819697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of interval-training on fatigue and functional capacities in Charcot-Marie-Tooth disease.
    El Mhandi L; Millet GY; Calmels P; Richard A; Oullion R; Gautheron V; Féasson L
    Muscle Nerve; 2008 May; 37(5):601-10. PubMed ID: 18335470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.
    Pareyson D; Reilly MM; Schenone A; Fabrizi GM; Cavallaro T; Santoro L; Vita G; Quattrone A; Padua L; Gemignani F; Visioli F; Laurà M; Radice D; Calabrese D; Hughes RA; Solari A; ;
    Lancet Neurol; 2011 Apr; 10(4):320-8. PubMed ID: 21393063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Employment status of patients with Charcot-Marie-Tooth type 1A.
    Bjelica B; Brankovic M; Bozovic I; Palibrk A; Kacar A; Rakocevic-Stojanovic V
    Acta Neurol Belg; 2022 Jun; 122(3):641-646. PubMed ID: 33491123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).
    Prukop T; Stenzel J; Wernick S; Kungl T; Mroczek M; Adam J; Ewers D; Nabirotchkin S; Nave KA; Hajj R; Cohen D; Sereda MW
    PLoS One; 2019; 14(1):e0209752. PubMed ID: 30650121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial.
    Micallef J; Attarian S; Dubourg O; Gonnaud PM; Hogrel JY; Stojkovic T; Bernard R; Jouve E; Pitel S; Vacherot F; Remec JF; Jomir L; Azabou E; Al-Moussawi M; Lefebvre MN; Attolini L; Yaici S; Tanesse D; Fontes M; Pouget J; Blin O
    Lancet Neurol; 2009 Dec; 8(12):1103-10. PubMed ID: 19818690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic Variability of Childhood Charcot-Marie-Tooth Disease.
    Cornett KM; Menezes MP; Bray P; Halaki M; Shy RR; Yum SW; Estilow T; Moroni I; Foscan M; Pagliano E; Pareyson D; Laurá M; Bhandari T; Muntoni F; Reilly MM; Finkel RS; Sowden J; Eichinger KJ; Herrmann DN; Shy ME; Burns J;
    JAMA Neurol; 2016 Jun; 73(6):645-51. PubMed ID: 27043305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombination hot spot in a 3.2-kb region of the Charcot-Marie-Tooth type 1A repeat sequences: new tools for molecular diagnosis of hereditary neuropathy with liability to pressure palsies and of Charcot-Marie-Tooth type 1A. French CMT Collaborative Research Group.
    Lopes J; LeGuern E; Gouider R; Tardieu S; Abbas N; Birouk N; Gugenheim M; Bouche P; Agid Y; Brice A
    Am J Hum Genet; 1996 Jun; 58(6):1223-30. PubMed ID: 8651299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postural stabilization and balance assessment in Charcot-Marie-Tooth 1A subjects.
    Lencioni T; Rabuffetti M; Piscosquito G; Pareyson D; Aiello A; Di Sipio E; Padua L; Stra F; Ferrarin M
    Gait Posture; 2014 Sep; 40(4):481-6. PubMed ID: 25082324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rehabilitation of Charcot-Marie-Tooth Disease].
    Tajima F; Nakamura T; Nishimura Y; Arakawa H; Kawasaki T; Ogawa T; Nishiyama K
    Brain Nerve; 2016 Jan; 68(1):59-68. PubMed ID: 26764300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised controlled trial protocol of foot and ankle exercise for children with Charcot-Marie-Tooth disease.
    Sman AD; Raymond J; Refshauge KM; Menezes MP; Walker T; Ouvrier RA; Burns J
    J Physiother; 2014 Mar; 60(1):55; discussion 55. PubMed ID: 24856942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.